SBIR/STTR Research Award

SBIR Phase I: Microneedle Bandage for Diabetic Foot Ulcers

Award identifier 8f45297dbf725a1e84a805b246612ec27602d4f786ab6ce03888653892d4c10bAwarding agency National Science Foundation

Award amount

$305,000

Program and phase

SBIR · Phase I

Award year

2025

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
National Science Foundation
Branch
Not reported
Recipient company
Therapeutic Bandage Products, Inc.
Proposal award date
2025-03-31
Contract end date
2026-03-31
UEI
PG5VB2XP8234
Solicitation number
NSF 24-579
Topic code
BM

Research abstract

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is an advanced wound care product that speeds healing of diabetic foot ulcers. These ulcers afflict millions of Americans, causing pain, loss of mobility, amputations, and potentially life-threatening infections. The average annual expenditure for diabetic foot care is $8,659 per patient resulting in cumulative costs of $9 to $13 billion in the United States alone. Foot ulceration often progresses to chronic infection, osteitis, and severe gangrene, resulting in over 100,000 amputations per year. The patented microneedle technology to be developed has significant commercial potential as a low-cost alternative for treating stalled wounds. By rapidly clearing the infections that block proper wound healing, the product will garner significant market share based on its ability to speed healing. The initial target market will generate approximately $4.2 M per year and is expected to accelerate rapidly when implemented nationwide. This will further increase as the product is adopted into adjacent markets. This Small Business Innovation Research (SBIR) Phase I project will develop an advanced wound care product that disinfects diabetic foot ulcers using a patented microneedle patch design that delivers three potent therapeutic agents, each of which participates in different aspects of wound healing. These agents are time-released to further enhance their function. Once the microneedle patch is applied to a recently debrided diabetic foot ulcer, a powerful antibiotic will be released to establish a bacterial killing zone in the dermal tissue of the wound. A second agent will prevent the re-formation of a bacterial biofilm, and a third agent known as a chemokine will attract and activate white blood cells to rapidly clean-up the infected area and kill any residual bacteria. Once the microneedle tips dissolve, a channel will open which facilitates wound drainage. Init

Technology keywords

Not reported

Agency intelligence

National Science Foundation

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.